Spravato Operations Series
Ketamine vs. Spravato Billing: Two Drugs, Two Revenue Models
IV/IM ketamine is mostly cash-pay because it is off-label for depression. Spravato is FDA-approved and insurance-billable — and REMS-bound. Running both means running two businesses under one roof.
The Regulatory Split Drives Everything Downstream
Racemic ketamine (IV or IM) and Spravato (intranasal esketamine) are pharmacological cousins, but from a billing standpoint they live in different universes, and the difference starts at the FDA label. Generic ketamine is FDA-approved as an anesthetic; its use for depression is off-label. Spravato is FDA-approved for treatment-resistant depression (including, since January 2025, as monotherapy) and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior — and it is dispensed only under a REMS, in certified healthcare settings, with mandatory post-dose monitoring.
From that split, everything else follows: who pays, what codes exist, what compliance applies, and what kind of operational machine each service line requires.
Coverage: Who Actually Pays
IV/IM Ketamine: Predominantly Cash-Pay
Because the depression indication is off-label, most commercial payers, Medicare, and Medicaid do not cover ketamine infusions for mood disorders, and most clinics run the service as self-pay with published per-infusion pricing. Exceptions exist — a few plans have covered it case-by-case, and coverage policies evolve — but no program should be financially modeled on the hope of ketamine reimbursement. Verify any payer’s written policy before assuming otherwise.
Spravato: Insurance-Billable, Behind Gates
Spravato is broadly covered by commercial payers, Medicare, and many Medicaid programs for its approved indications — but access runs through prior authorization, benefit-pathway determination (medical vs. pharmacy benefit), REMS-certified delivery, and documentation-heavy claims. Covered does not mean simple; it means the revenue is administered rather than collected at the desk. See the prior authorization playbook.
Coding: What a Claim Even Looks Like
Spravato has purpose-built codes. Medicare commonly pays through the bundled codes G2082 (sessions up to 56 mg) and G2083 (over 56 mg — in practice, 84 mg sessions), which fold the visit, drug, and two-hour observation into one payment; separate E/M is generally not billable the same day under the bundle. Commercial and Medicaid claims commonly carry the drug as HCPCS J0013, billed per 1 mg unit — J0013 replaced S0013 effective January 1, 2026, and some payers handled the transition unevenly, so confirm which code each payer currently accepts — alongside an E/M visit and, where the payer’s policy allows, prolonged clinical-staff observation codes (99415/99416) with documented start and stop times. Full detail in our Spravato billing guide.
IV/IM ketamine has no depression-specific codes at all. When clinics bill insurance anyway, claims are typically assembled from generic infusion/injection administration codes with the drug as an unclassified or generic HCPCS entry — and payers routinely deny them for mood indications as off-label or experimental. In practice, most programs skip the pretense: a transparent cash price per infusion, a good-faith estimate, and clean self-pay bookkeeping outperform a denial-generation machine. If a patient wants to seek out-of-network reimbursement themselves, provide a superbill and set expectations honestly.
One compliance note for mixed programs: never blur the lines. Billing a payer for Spravato-style monitoring codes around a cash ketamine infusion, or disguising an off-label infusion inside covered-service coding, is not creative billing — it is a false-claims risk. Keep the two lines’ documentation and charge structures cleanly separated.
Running Both: The Program-Mix Operational Reality
Many interventional psychiatry clinics offer both, and the combination is sensible — the two lines hedge each other. But operationally you are running two businesses that happen to share chairs:
- Two revenue engines: The ketamine line needs price lists, point-of-service collection, and package/membership bookkeeping. The Spravato line needs benefit verification, authorization tracking, claims, and denial follow-up. Different staff skills, different failure modes, different dashboards.
- Two compliance regimes: Spravato sessions carry REMS obligations — certified setting, enrolled patients, two-hour monitored windows, specific documentation (see the REMS compliance workflow). Ketamine infusions carry their own clinical monitoring standards and informed-consent burden for off-label use, but no REMS. Staff need to know which protocol applies to the patient in chair three.
- Two scheduling profiles: Both occupy long monitored blocks, but Spravato cadence is protocol-driven (twice weekly induction tapering to maintenance) while infusion series are more variable. A shared calendar needs to protect Spravato induction pairs while filling around them — capacity design, not luck.
- Two financial conversations: The patient deciding between a covered Spravato course (copays, deductible, PA wait) and a cash infusion series (immediate start, out of pocket) deserves an accurate, non-promotional comparison. Front-desk scripts matter; steering patients toward whichever line is easier for the clinic to collect is a fast way to lose trust.
- One P&L discipline: Track the two lines’ margins separately. Cash ketamine revenue is immediate but capped by local price tolerance; Spravato revenue is durable and payer-backed but leaks wherever auth tracking, verification, or claims follow-up is weak. Clinics that pool the numbers usually discover one line has been quietly subsidizing the other’s broken operations.
This split-brain problem — one calendar, two revenue models — is exactly where purpose-built tooling and disciplined revenue cycle management pay for themselves. We support programs on both sides of the mix, and build the software that keeps the lines visible; see custom software and automation.
Running Ketamine and Spravato Under One Roof?
We help clinics keep both revenue models honest — cash-line pricing discipline on one side, authorization and claims infrastructure on the other.
Common Questions
Why does insurance cover Spravato but not ketamine infusions?
Spravato is FDA-approved for treatment-resistant depression and for depressive symptoms in MDD with acute suicidal ideation or behavior, which gives payers an approved indication to cover. IV/IM ketamine for depression is off-label use of an anesthetic, and most payers classify it as unproven or experimental for mood disorders. Individual policies vary, so always check the specific plan.
Can we bill insurance for ketamine infusions at all?
You can submit claims using generic administration codes and an unclassified drug code, but for depression indications most payers deny them, and appeals rarely succeed. Most programs run infusions as transparent cash-pay and, where the patient wants to try out-of-network reimbursement, provide a superbill with honest expectations.
What codes are used for Spravato billing?
Medicare commonly uses bundled G2082 (up to 56 mg) and G2083 (over 56 mg). Commercial and Medicaid claims commonly carry the drug as J0013 per 1 mg (replacing S0013 as of January 1, 2026) with an E/M visit and, where policy allows, prolonged observation codes 99415/99416. Verify current coding with each payer.
Is Spravato more profitable than cash-pay ketamine?
It depends entirely on payer mix, contracted rates, drug acquisition pathway, and how tight your authorization and claims operations are. Spravato revenue is payer-backed and durable but administratively expensive; cash ketamine is immediate but price-capped by the local market. Model them separately — the answer differs clinic by clinic, and we make no revenue promises either way.
Does the Spravato REMS apply to ketamine infusions?
No. The REMS is specific to Spravato (esketamine). Ketamine infusions carry their own monitoring and consent standards, but not REMS certification, patient enrollment, or REMS documentation requirements.
Can the same staff run both service lines?
Clinically, often yes, subject to scope and training. Operationally, the billing workflows should be separated: point-of-service collection and package tracking for the cash line, verification, authorization tracking, and claims follow-up for the Spravato line. Cross-training is fine; merged workflows are how errors happen.